Insmed Incorporated (NASDAQ:INSM) CEO Sells $479,192.80 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 6,830 shares of Insmed stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,412,107.84. This trade represents a 2.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50.
• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00.

Insmed Trading Up 3.3 %

Shares of NASDAQ INSM opened at $72.53 on Friday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company’s fifty day moving average is $75.34 and its 200-day moving average is $73.59. The stock has a market cap of $13.19 billion, a price-to-earnings ratio of -12.97 and a beta of 1.07.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Investors Weigh In On Insmed

Several large investors have recently made changes to their positions in INSM. Elequin Capital LP acquired a new position in Insmed in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC grew its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in Insmed in the 4th quarter valued at approximately $47,000. Finally, NBC Securities Inc. bought a new stake in Insmed in the 1st quarter valued at approximately $49,000.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. Guggenheim reissued a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.